Stock analysts at SunTrust Banks began coverage on shares of Gilead Sciences (NASDAQ:GILD) in a report released on Tuesday, The Fly reports. The brokerage set a “hold” rating and a $70.00 price target on the biopharmaceutical company’s stock. SunTrust Banks’ price objective suggests a potential upside of 8.54% from the stock’s current price.
A number of other equities research analysts also recently issued reports on the company. Citigroup set a $78.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Maxim Group cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. Credit Suisse Group reduced their price objective on Gilead Sciences from $70.00 to $67.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 31st. Robert W. Baird set a $76.00 price objective on Gilead Sciences and gave the company a “hold” rating in a research note on Friday, October 25th. Finally, Mizuho set a $81.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Tuesday, October 15th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the stock. Gilead Sciences has an average rating of “Buy” and a consensus target price of $78.87.
NASDAQ GILD traded down $0.15 on Tuesday, hitting $64.49. 13,933 shares of the stock traded hands, compared to its average volume of 6,286,513. The business’s fifty day moving average is $64.10 and its two-hundred day moving average is $65.28. Gilead Sciences has a 12 month low of $60.32 and a 12 month high of $72.90. The firm has a market capitalization of $82.72 billion, a price-to-earnings ratio of 10.49, a PEG ratio of 3.47 and a beta of 1.09. The company has a debt-to-equity ratio of 1.11, a quick ratio of 2.87 and a current ratio of 2.96.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.74 by $0.01. Gilead Sciences had a return on equity of 37.50% and a net margin of 12.04%. The firm had revenue of $5.60 billion for the quarter, compared to the consensus estimate of $5.61 billion. During the same quarter in the prior year, the business posted $1.84 earnings per share. The business’s quarterly revenue was up .1% on a year-over-year basis. Analysts expect that Gilead Sciences will post 6.66 EPS for the current fiscal year.
In other Gilead Sciences news, Director Olsen Per Wold sold 4,908 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $63.91, for a total transaction of $313,670.28. Following the sale, the director now directly owns 102,762 shares of the company’s stock, valued at approximately $6,567,519.42. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Brett A. Pletcher sold 5,677 shares of Gilead Sciences stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $63.31, for a total value of $359,410.87. Following the sale, the executive vice president now directly owns 21,521 shares in the company, valued at $1,362,494.51. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 17,288 shares of company stock worth $1,108,682. Insiders own 0.20% of the company’s stock.
A number of institutional investors have recently bought and sold shares of GILD. Private Trust Co. NA bought a new stake in Gilead Sciences in the 2nd quarter worth approximately $203,000. DNB Asset Management AS grew its position in shares of Gilead Sciences by 8.8% during the 2nd quarter. DNB Asset Management AS now owns 316,426 shares of the biopharmaceutical company’s stock valued at $21,378,000 after acquiring an additional 25,719 shares during the period. Denali Advisors LLC grew its position in shares of Gilead Sciences by 14.5% during the 2nd quarter. Denali Advisors LLC now owns 163,003 shares of the biopharmaceutical company’s stock valued at $11,012,000 after acquiring an additional 20,700 shares during the period. Carroll Financial Associates Inc. grew its position in shares of Gilead Sciences by 22.5% during the 2nd quarter. Carroll Financial Associates Inc. now owns 3,946 shares of the biopharmaceutical company’s stock valued at $266,000 after acquiring an additional 724 shares during the period. Finally, Cooper Financial Group grew its position in shares of Gilead Sciences by 4.3% during the 2nd quarter. Cooper Financial Group now owns 3,604 shares of the biopharmaceutical company’s stock valued at $243,000 after acquiring an additional 149 shares during the period. 80.03% of the stock is currently owned by institutional investors and hedge funds.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Further Reading: Percentage Decliners
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.